Technology | June 20, 2014

FDA Approves Gadavist (Gadobutrol) Injection as First Contrast Agent for Breast MRI in United States

FDA Approves Gadavist (Gadobutrol) Injection as First Contrast Agent for Breast MRI in United States

June 20, 2014 — Bayer HealthCare announced the U.S. Food and Drug Administration (FDA) approved a new indication for Gadavist (gadobutrol) injection for intravenous use with magnetic resonance imaging (MRI) of the breast to assess the presence and extent of malignant breast disease. The approval is based on priority review of two multicenter, Phase III studies (GEMMA-1 and GEMMA-2) conducted in 13 countries.

"The Phase 3 GEMMA studies demonstrate that Gadavist-enhanced breast MRI provided a statistically significant improvement in the identification of the extent of breast cancer versus unenhanced MRI," said GEMMA principal investigator Gillian Newstead, M.D., FACR, from the University of Chicago Medical Center. "This is an important diagnostic tool for healthcare professionals with breast cancer patients. Breast MRI with Gadavist provides important visibility for assessment of malignant breast disease and for treatment planning."

"While we've made great strides in the United States with early detection, one in five women will still have undetected breast cancer following a mammogram," said Dennis Durmis, head of the Americas region for Bayer's radiology and interventional business. "The FDA's swift action in approving Gadavist for contrast-enhanced breast MRI is consistent with recent guidelines from cancer and breast imaging societies."

The GEMMA studies were used to investigate the diagnostic efficacy of Gadavist-enhanced breast MRI. In total, 787 patients with recently diagnosed breast cancer from 13 countries were enrolled (GEMMA-1: 390 women; GEMMA-2: 396 women and one man). In each study, MRI images were analyzed by three independent radiologists. These readers confirmed that Gadavist-enhanced breast MRI improved ability to assess the presence and extent of breast cancer when compared to images from unenhanced breast MRI.

Key findings for these studies included:

• Gadavist-enhanced breast MRI demonstrated superior sensitivity (range: 80-89 percent) for the presence and extent of malignant disease compared to unenhanced breast MRI (range: 37-73 percent) for all six readers.

• A true-negative rate (specificity) of >80 percent for breasts without malignant disease was confirmed for Gadavist-enhanced breast MRI by 5 of 6 readers.

The studies did reveal that in breasts with malignancy, Gadavist-enhanced breast MRI overestimated the histologically confirmed extent of malignancy in the diseased breast in up to 50 percent of the patients.

Three additional radiologists in each study read X-ray mammography alone. For these readers, over both studies, sensitivity for the presence and extent of malignancy ranged from 68 to 73 percent and specificity ranged from 86 to 94 percent in non-malignant breasts.

Final study findings will be presented at an upcoming medical meeting.

For more information: www.healthcare.bayer.com

Related Content

LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...
Warm Springs Health & Wellness Center Implements Digisonics Solution for OB Ultrasound
News | Ultrasound Women's Health | June 17, 2019
Warm Springs Health & Wellness Center in Warm Springs, Ore., has selected the Digisonics OB PACS (picture archiving...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

News | Mammography | June 14, 2019
Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused...
SyMRI Software Receives FDA Clearance for Use With Siemens MRI Systems
Technology | Magnetic Resonance Imaging (MRI) | June 14, 2019
SyntheticMR announced U.S. Food and Drug Administration (FDA) clearance for clinical use of its SyMRI Image and SyMRI...
Ikonopedia Showcases Risk Assessment and Resolution Manager Tools at SIIM and AHRA
News | Mammography Reporting Software | June 13, 2019
Ikonopedia will showcase its suite of structured breast reporting and Mammography Quality Standards Act (MQSA)...
iCAD Introduces ProFound AI for 2D Mammography in Europe
News | Artificial Intelligence | June 13, 2019
iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to...
Three Palm Software Releases WorkstationOne Version 1.8.8
Technology | Mammography Reporting Software | June 12, 2019
Three Palm Software announced the release of the 1.8.8 version of its breast imaging workstation, WorkstationOne. This...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...